Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Most people know roughly what a bottle of vitamin D supplements might cost them, so the lack of information on cost is not a significant gap. We appreciate that the story provided data showing the large and growing amount our society is spending on vitamin D supplements ($430 million in 2009), with apparently little health benefit to show for it. The story was mostly concerned with discussing the lack of benefit from taking extra vitamin D and calcium. And in this area it excels. While the story does lack precision when it suggests that adolescent girls should be getting more calcium (it never specifies how much they are getting now, how much more they’d need to meet the recommendations, or what benefits they might expect from this increased intake), it would be difficult for a journalist to come up with any sort of quantifiable benefit or harm estimate from the IOM report. The story captured the overall gist of the problem, which is that the evidence base is complex and still inadequate. The story notes that, contrary to the claims of many advocates for increased supplemental vitamin D, there is evidence that high levels of vitamin D may have adverse effects, such as increased risk for fractures and an increase in the overall death rate. The story also explained that too much calcium has been linked to increased risk of kidney stones and, more tentatively, heart disease. The story did a good job of describing how the expert committee conducted its review and what evidence they found. Importantly, it noted that  claims of benefit from extra vitamin D are based on observational studies that most scientists agree “cannot determine cause and effect.” We also like that the story solicited opinions from a variety of experts with no obvious stake in the controversy. This produced a number of quotes that emphasized the need for restraint when interpreting the research on vitamin D. Examples: “I think this report will make people more cautious” and “The onus is on the people who propose extra calcium and vitamin D to show it is safe before they push it on people.” Although we agree with the story’s skeptical overall message, we think it may have slammed the door just a bit too hard on the possibility of benefit from supplemental vitamin D. While claims of benefit may not be supported by the currently available evidence, they have not been conclusively disproved in randomized controlled studies, either. In fact, research is now underway to determine whether the benefits found in observational studies of vitamin D can be replicated in more rigorously designed trials. The story probably should have mentioned this research, and left the door to potential benefits open just a crack. No disease-mongering here. The diversity of independent voices included in this story is a real strength. Although it solicits the obligatory comment from a supplement industry spokesman, it didn’t go out of its way to find any of the more widely known vitamin D experts, some of whom have been issuing recommendations that are untenable based on current evidence. The enthusiasm of some of these researchers might be explained by their significant career and financial interests in promoting vitamin D. Not applicable for this story. The approaches discussed are not new, and there’s not really any alternative to getting adequate amounts of these essential nutrients. The availability of vitamin D from diet, sunlight and supplements is clear from the story. The novelty of vitamin D and calcium is not really in question, so we’ll call this not applicable. This story was not based on a news release. Claim: Report Questions Need for 2 Diet Supplements

Answer: In one particularly effective passage, the story quoted a representative of a supplement industry group who disagreed with the report, saying that higher levels of vitamin D could be beneficial. But it then segued immediately into an explanation of why claims from supplementation advocates “are not supported by the available evidence.” The key problem, as the story points out, is that these claims are based almost exclusively on observational studies that can’t prove cause and effect and are often skewed by factors the researchers haven’t accounted for. Proponents of supplementation also have tended to downplay the possibility that higher doses of vitamin D and calcium might cause harm–a stance which the story notes may not be justified. We applaud this story’s effort to show readers where the weight of the evidence lies on this issue. Vitamin D is the latest in a long line of “miracle” nutrients that people have turned to in the hope of improving their health. As we’ve learned from copious previous experience, these supplements rarely work as advertised and can sometimes cause harm at the higher doses people often think will be beneficial for them. More isn’t necessarily better when it comes to vitamin D–or most other health care interventions for that matter.


Question: Paragraph: "It is less surprising that neither story discussed costs, given that so few stories do. But sample costs could have been obtained by calling any of the numerous medical marijuana outlets in states where it is legal. Both stories did a decent job of quantifying the benefits.This story provided more details, though, including the differences in patient experiences between the three different concentrations of marijuana. It also repeated this important bit of information: ""There was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments."" The story also does a great job of pointing out that the treatment duration of five days in each dosage phase is too short to judge utility for chronic pain, which is a long-term affliction. Neither story actually quantified the harms, but they both noted there were side effects. This story did a better job, though, by noting that the only dose that seemed to work also seemed to produce the most side effects and by raising the issue of long-term safety concerns. It also was the only story to answer the question that readers surely would have when reading about an illegal narcotic being used as medicine. Did these patients feel high as a result? This story says that most did not. Because of the additional information and context, the rating here is satisfactory. This story, unlike the competing WebMD piece, establishes in the first sentence — even in the first three words — that this was ""a small study."" It then discusses the limitations of the study at several points. The second sentence says, ""The pain reduction was ""modest"" – less than 1 point on an 11-point scale for the strongest marijuana – and patients reported no overall difference in their quality of life based on what they smoked."" The writer elegantly and succinctly described the study design — a complex randomized cross-over trial with double blinding and delved into an important feature of the study, that the subjects in retrospect may have been able to detect during which phase of their experience they inhaled placebo versus the most potent drug. This story avoids disease mongering, and, in fact, goes beyond that to note how few people actually suffer from the type of chronic pain that was the subject of the study: ""About 1 to 2 percent of adults in the U.S."" The story quotes two outside experts, one of whom is completely independent from the study and the journal, Dr Andrea Hohmann. Beyond that, we would bet that the reporter spent more time interviewing Dr. Mark Ware, the lead researcher, or at least asked tougher questions. Because Ware is more measured in this story than in the WebMD story. He even goes so far as to say, ""What about long-term safety issues?"" he asked. ""These need to be considered before the drug becomes prescribable."" As with the WebMD story, it would have been nice to see who funded the research. Unlike the WebMD story, this one did not point out the conflicts of interest of Dr. Henry McQuay. This story talks about a range of treatment options and even has the study’s lead author suggesting, that ""these patients should also be getting behavioral and physical therapy."" Strangely, neither story we reviewed pointed out that marijuana is illegal in most states and in Canada, where the study took place. The story could have, at a minimum, mentioned which states have medical marijuana laws or talked about whether any other countries currently allow cannabis to be sold in pill form the way it was used in this study. The story alludes to the fact that this study ""supports a limited number of trials that have suggested marijuana may be helpful for people suffering from chronic pain,"" indicating that the treatment is not very novel at all. It would have been nice to see more context around that. The WebMD story provides a little more information in this regard. If the news release is to be believed, ""This is the first trial to be conducted where patients have been allowed to smoke cannabis at home and to monitor their responses, daily"". That could have been made clear. The story goes well beyond the release. Here’s the release." Claim: Pot may provide some chronic pain relief: study

Answer: The story did a great job evaluating the evidence, providing outside voices, discussing alternatives to marijuana smoking, and presenting both the benefits and the potential harms. It could have done a better job discussing possible costs, availability and conflicts of interest. From the headline to the last sentence, this report avoided overstatement of the applicability of the potential benefit and used clear incisive language that left the reader with a good understanding of the study and its implications. This topic lends itself to jokey, pun-filled writing, but this story played it straight. Chronic pain can ruin lives, and a breakthrough with an alternative approach would be important news. As this story makes clear, until some larger studies with fewer limitations are undertaken, we are far from the point where marijuana can be considered a safe and effective treatment for chronic pain.


Question: Paragraph: The death toll rose by 743 on Tuesday, the second highest daily tally since the outbreak emerged in northern regions on Feb. 21, and up steeply from the 602 recorded on Monday. Italy has seen more fatalities than any other country, with latest figures showing that 6,820 people have died from the infection in barely a month. The total number of confirmed cases hit 69,176 on Tuesday, but with Italy testing only people with severe symptoms, the head of the Civil Protection Agency said the true number of infected people was probably 10 times higher. “A ratio of one certified case out of every 10 is credible,” Angelo Borrelli told La Repubblica newspaper, indicating he believed some 700,000 people could have been infected. The latest data comes as a disappointment to a country that has been in lockdown for two weeks, with schools, bars and restaurants shut and Italians forbidden from leaving their homes for all but essential needs. On Monday the government closed all businesses not deemed to be essential to the nation’s supply chain of vital requirements, and after the latest figures Prime Minister Giuseppe Conte stiffened fines for people leaving their homes to up to 3,000 euros ($3,225) from a previous maximum of 206 euros. “Every one of us must play our part,” he told reporters at a news conference held by remote video link to avoid contagion. “If everyone obeys the rules they don’t only protect themselves and their loved ones, but they will enable the whole national community to come out of this emergency.”  Current restrictions are due to remain in place until April 3, but there is speculation the date will have to be pushed back given the continual rise in cases across the country. A decree issued on Tuesday gave the government the power to extend the deadline to July 31. However, Conte denied planning to keep the lockdown in place until that date, saying he hoped to loosen curbs “well before then”. Investment bank Goldman Sachs forecast on Tuesday that the Italian economy, already teetering on recession before the outbreak hit, would shrink by more than 11% this year. Economy Minister Roberto Gualtieri told parliament he expected a contraction of “a few percentage points”. The Civil Protection Agency said the biggest difficulty facing the health service was a shortage of masks and ventilators - a problem that has dogged hospitals since the start of the outbreak. Underscoring the problem, the regional governor of Veneto, Luca Zaia, ordered the confiscation of ventilators at veterinary surgeries, saying they could be converted to human use. With other countries looking to hoard their own medical supplies, a consortium of Italian textile and fashion companies have converted their production lines and will soon be able to produce half the required amount of masks. “(This) will give our system the ammunition that we need in order to fight this war and avoid our total dependence on imports,” Domenico Arcuri, the national commissioner for the emergency, told reporters. The government has said a number of industrial sectors, including medical suppliers, must keep operating during the crisis, but there is growing unhappiness amongst some unions who think the list of strategic concerns is too wide. Workers in the metal, chemical, textile, rubber-plastic and paper industries are expected to go on strike on Wednesday, alarming the government, which is holding talks with unions to try to stave off the stoppages. “The last thing that Italy can allow itself is industrial conflict in a situation of national emergency,” deputy Economy Minister Antonio Misiani told SkyTG24 television. Claim: Italian coronavirus deaths jump, dashing hopes that worst was over.

Answer:
Fatalities in Italy from coronavirus have surged in the last 24 hours, the Civil Protection Agency said on Tuesday, dashing hopes the epidemic in the world’s worst hit country was easing after more encouraging numbers in the previous two days.